The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells

详细信息    查看全文

• 作者：Bin Wang ; Zhenhong Ni ; Xufang Dai ; Liyan Qin ; Xinzhe Li ; Liang Xu…
• 关键词：ABT ; 263 ; Mcl ; 1 ; Stability ; HCC
• 刊名：Molecular Cancer
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：13
• 期：1
• 全文大小：918 KB
• 参考文献：1. El-Serag, HB, Rudolph, KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: pp. 2557-2576 CrossRef
  2. Tanaka, S, Arii, S (2012) Molecular targeted therapies in hepatocellular carcinoma. Semin Oncol 39: pp. 486-492 CrossRef
  3. Zender, L, Spector, MS, Xue, W, Flemming, P, Cordon-Cardo, C, Silke, J, Fan, ST, Luk, JM, Wigler, M, Hannon, GJ, Mu, D, Lucito, R, Powers, S, Lowe, SW (2006) Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125: pp. 1253-1267 CrossRef
  4. Lessene, G, Czabotar, PE, Colman, PM (2008) BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 7: pp. 989-1000 CrossRef
  5. Yang, TM, Barbone, D, Fennell, DA, Broaddus, VC (2009) Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids. Am J Respir Cell Mol Biol 41: pp. 14-23 CrossRef
  6. Tabuchi, Y, Matsuoka, J, Gunduz, M, Imada, T, Ono, R, Ito, M, Motoki, T, Yamatsuji, T, Shirakawa, Y, Takaoka, M, Haisa, M, Tanaka, N, Kurebayashi, J, Jordan, VC, Naomoto, Y (2009) Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer. Int J Oncol 34: pp. 313-319
  7. Cho, HJ, Kim, JK, Kim, KD, Yoon, HK, Cho, MY, Park, YP, Jeon, JH, Lee, ES, Byun, SS, Lim, HM, Song, EY, Lim, JS, Yoon, DY, Lee, HG, Choe, YK (2006) Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells. Cancer Lett 237: pp. 56-66 CrossRef
  8. Sartorius, UA, Krammer, PH (2002) Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 97: pp. 584-592 CrossRef
  9. Yang, Y, Zhu, J, Gou, H, Cao, D, Jiang, M, Hou, M (2011) Clinical significance of Cox-2, Survivin and Bcl-2 expression in hepatocellular carcinoma (HCC). Med Oncol 28: pp. 796-803 CrossRef
  10. Chun, E, Lee, KY (2004) Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells. Biochem Biophys Res Commun 315: pp. 771-779 CrossRef
  11. Davids, MS, Letai, A (2012) Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol 30: pp. 3127-3135 CrossRef
  12. Gandhi, L, Camidge, DR, Ribeiro de Oliveira, M, Bonomi, P, Gandara, D, Khaira, D, Hann, CL, McKeegan, EM, Litvinovich, E, Hemken, PM, Dive, C, Enschede, SH, Nolan, C, Chiu, YL, Busman, T, Xiong, H, Krivoshik, AP, Humerickhouse, R, Shapiro, GI, Rudin, CM (2011) Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 29: pp. 909-916 CrossRef
  13. Rudin, CM, Hann, CL, Garon, EB, Ribeiro de Oliveira, M, Bonomi, PD, Camidge, DR, Chu, Q, Giaccone, G, Khaira, D, Ramalingam, SS, Ranson, MR, Dive, C, McKeegan, EM, Chyla, BJ, Dowell, BL, Chakravartty, A, Nolan, CE, Rudersdorf, N, Busman, TA, Mabry, MH, Krivoshik, AP, Humerickhouse, RA, Shapiro, GI, Gandhi, L (2012) Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res 18: pp. 3163-3169 CrossRef
  14. Hikita, H, Takehara, T, Shimizu, S, Kodama, T, Shigekawa, M, Iwase, K, Hosui, A, Miyagi, T, Tatsumi, T, Ishida, H, Li, W, Kanto, T, Hiramatsu, N, Hayashi, N (2010) The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepato
• 刊物主题：Cancer Research; Oncology;
• 出版者：BioMed Central
• ISSN：1476-4598

文摘

Background Hepatocellular carcinoma (HCC) is one of the major causes of mortality. ABT-263 is a newly synthesized, orally available Bcl-2/xL inhibitor that shows promising efficacy in HCC therapy. ABT-263 inhibits the anti-apoptotic activity of Bcl-2 and Bcl-xL, but not Mcl-1. Previous reports have shown that ABT-263 upregulates Mcl-1 in various cancer cells, which contributes to ABT-263 resistance in cancer therapy. However, the associated mechanisms are not well known. Methods Western blot, RNAi and CCK-8 assays were used to investigate the relationship between Mcl-1 upregulation and ABT-263 sensitivity in HCC cells. Real-time PCR and Western blot were used to detect Mcl-1 mRNA and protein levels. Luciferase reporter assay and RNA synthesis inhibition assay were adopted to analyze the mechanism of Mcl-1 mRNA upregulation. Western blot and the inhibition assays for protein synthesis and proteasome were used to explore the mechanisms of ABT-263-enhanced Mcl-1 protein stability. Trypan blue exclusion assay and flow cytometry were used to examine cell death and apoptosis. Results ABT-263 upregulated Mcl-1 mRNA and protein levels in HCC cells, which contributes to ABT-263 resistance. ABT-263 increased the mRNA level of Mcl-1 in HCC cells by enhancing the mRNA stability without influencing its transcription. Furthermore, ABT-263 increased the protein stability of Mcl-1 through promoting ERK- and JNK-induced phosphorylation of Mcl-1Thr163 and increasing the Akt-mediated inactivation of GSK-3β. Additionally, the inhibitors of ERK, JNK or Akt sensitized ABT-263-induced apoptosis in HCC cells. Conclusions ABT-263 increases Mcl-1 stability at both mRNA and protein levels in HCC cells. Inhibition of ERK, JNK or Akt activity sensitizes ABT-263-induced apoptosis. This study may provide novel insights into the Bcl-2-targeted cancer therapeutics.